Join our daily newsletter At The Bell to receive exclusive market insights
- Pharmaceutical company Starpharma has launched its VivaGel product in the U.K.
- Viva Gel is the company’s flagship product and its latest foray into the women’s health treatment industry
- The product is being sold through pharmacy giant Mundipharma
- Starpharma’s share price is down nearly one per cent today, currently sitting at $1.42 cents per share
Starpharma has launched its flagship VivaGel product in the U.K.
The product is being sold through pharmacy giant Mundipharma, who is also launching VivaGel across Europe. Launches are also planned for Asia in the near future, dependent on regulatory approvals.
“Starpharma and Mundipharma are working closely together to bring this breakthrough product to European women suffering from BV,” Starpharma’s CEO Dr Jackie Fairley said.
The VivaGel products are non-antibiotic treatments for bacterial vaginosis. The product comes in gel form and as a condom.
Bacterial vaginosis is a common condition affecting women, caused by a build up various bacteria on the vagina. Globally, one in three women suffer from the condition.
Published in the International Journal of Microbiology, bacterial vaginosis is classified as a “global concern” based on its risk of spreading sexually transmitted diseases.
Starpharma and Mundipharma said the two companies are continuing to work on gaining regulatory approvals world-wide and continuing the roll out of its products.
Heading into the last hour of today’s trade, Starpharma’s share price is down 2.26 per cent, currently sitting at $1.30 per share.
